MedTrace Logo

Helicobacter Pylori and Proton Pump Inhibitor

NCT02449941 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 30

Last updated 2016-12-06

No results posted yet for this study

Summary

The purpose of this study is to know the distribution of HP in stomach before use of PPI, during use of PPI, and after stop of PPI.

Conditions

  • Helicobacter Infections

Interventions

DRUG

PPI (proton pump inhibitor)

1. Pre ESD (endoscopic submucosal dissection) * Assessment atrophy and metaplasia in stomach, Check Helicobacter pylori * Use of PPI for 2 months 2. Post ESD 1 (After 2 months) * Assess the distribution of helicobacter pylori after using PPI. * Stop of PPI 3. Post ESD 2 (After 4 months) * Assess the distribution of helicobacter pylori after stop of PPI.

Sponsors & Collaborators

  • Asan Medical Center

    lead OTHER

Principal Investigators

  • Ji Yong Ahn, Professor · Asan Medical Center

Eligibility

Min Age
19 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2014-03-31
Primary Completion
2016-12-31
Completion
2016-12-31

Countries

  • South Korea

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02449941 on ClinicalTrials.gov